Global Cystic Fibrosis Therapeutics Market Research Report

 

As per the research conducted by GME, the Global Cystic Fibrosis Therapeutics Market will grow with a CAGR value of 13.5% by 2026. Cystic fibrosis is becoming more prevalent, resulting in increased awareness, technological improvements, strong pipeline prospects, and expanding R&D initiatives which are some of the factors to influence the growth of the market. The disease has no permanent cure but the symptoms and complications can be reduced by early diagnosis and proper treatment.

Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Cystic Fibrosis Therapeutics Market - Forecast to 2026” 

https://www.globalmarketestimates.com/market-report/global-cystic-fibrosis-therapeutics-market-3184

By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration (Oral drugs, Inhaled drugs), By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis

Key Market Insights

·       Mucoviscidosis often referred to as cystic fibrosis, is a hereditary condition that is characterized by improper sodium and chloride transport through an epithelium, resulting in a lung infection that impairs breathing.

·       CFTR Modulators are leading the market as per drug class and inhalation method as per route of administration

·       One of the key factors expected to grow the market in the approaching years is increasing awareness among healthcare professionals and patients about advanced treatments in the APAC market

·       Laurent Pharmaceuticals, Spyryx Biosciences, Zambon Pharmaceuticals, AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT - Advanced Inhalation Therapies; Alaxia; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Alcresta Therapeutics, Inc.; Allergan, AstraZeneca, Translate Bio, Morphic Therapeutic, Galecto Biotech, and Lung Therapeutics among others are the top players in the cystic fibrosis therapeutics market

Browse the Report @ https://www.globalmarketestimates.com/market-report/global-cystic-fibrosis-therapeutics-market-3184

 Drug Class Outlook (Revenue, USD Billion, 2021-2026)

·       Pancreatic Enzyme Supplements

·       Mucolytics

·       Bronchodilators

·       CFTR Modulators

Route of Administration Outlook (Revenue, USD Billion, 2021-2026)

·       Oral drugs

·       Inhaled drugs

Regional Outlook (Revenue, USD Billion, 2021-2026)

North America                                                                                 

• The U.S.
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC

 

Central & South America

• Brazil
• Argentina
• Rest of CSA

Middle East & Africa

• Saudi Arabia
• UAE
• Rest of MEA

Contact: Tracy Simon

Email address: tracy.simon@globalmarketestimates.com

Phone Number: +16026667238

Website: https://www.globalmarketestimates.com/

Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php